Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Hough S, Talbott M, Fynan T, Patel S, Dinner S, Perez LE, Curtin P, Vasu S, Rugo HS, Westervelt P, Schwartzberg LS, Armitage JO, Blayney DW, Chavez J, Kloth DD, Rampal R, Wadleigh M, Griffiths EA, Mukherjee S, Poust A, Vadhan-Raj S, Kuter DJ, Lyman GH, Burns JL, Crawford J, Gojo I, Shayani S, Mably M, Roy V, Saad AA, Pluchino L, Becker PS
J Natl Compr Canc Netw 15 1520-1541 12/01/2017

Abstract

Myeloid growth factors (MGFs) are given as supportive care to patients receiving myelosuppressive chemotherapy to reduce the incidence of neutropenia. This selection from the NCCN Guidelines for MGFs focuses on the evaluation of regimen- and patient-specific risk factors for the development of febrile neutropenia (FN), the prophylactic use of MGFs for the prevention of chemotherapy-induced FN, and assessing the risks and benefits of MGF use in clinical practice.

Full Text